EDDING GENOR

Edding Genor opened lower and continued to decline in the morning session, dropping from HKD 1.570 to HKD 1.510, a decline of 5.3%, with intraday low at HKD 1.510 and thin trading volume of only 395,500 shares and turnover of approximately HKD 613,000. The pressure was mainly driven by a sub-licensing deal collapse following an upstream license termination and the company's profit warning of a net loss of RMB 60-70 million for H1 2026 versus a year-ago profit, which dampened market sentiment. Financially, Q4 2025 operating revenue rose 20.5% YoY to HKD 751.7 million and net profit surged 156.8% YoY to HKD 158.3 million, with a low P/E of 6.79x and P/B of 0.7x. However, the stock has plunged 73% from its 52-week high of HKD 5.6 and is down 48% YTD, trading at HKD 1.51, still below the 20-day MA of HKD 1.667 and 60-day MA of HKD 1.768, reflecting persistent technical weakness.

Edding Genor opened flat at HKD 1.650 in the morning session, then edged up to HKD 1.675, gaining 5.35%, albeit on thin volume of only 8,500 shares. Recent share buybacks disclosed at HKD 1.85-1.92 and the earlier US$48.4 million realization from selling its Candid stake to UCB provided support. However, the stock remains 70% below its 52-week high of HKD 5.6 and trades below both the MA20 (1.701) and MA60 (1.782), indicating weak medium-term momentum. Q4 revenue grew 20.5% YoY and net profit surged 156.8% YoY, yet the price failed to hold above MA20, suggesting lingering concerns about the rebound's sustainability.

Edding Genor Group slumped in afternoon trading, closing at HKD 1.605 as of 13:17 BJ, down 5.59% from previous close of HKD 1.700, with intraday range spanning HKD 1.605 to 1.700. The session tracked a spike-and-retreat pattern: opening flat at HKD 1.700, it plunged sharply after lunch on volume of 36,000 shares (turnover HKD 58,263). The drop was triggered by collapse of its sub-licensing deal with Jing Zhu after upstream license termination, jeopardizing a potential US$16.7 million milestone. Financially, Q4 2025 revenue hit HKD 752 million (+20.5% YoY), net profit HKD 158 million (+156.82% YoY), operating profit HKD 199 million (+69.24% YoY), net margin 21.06%, and EPS HKD 0.0787 (+112.91% YoY). Yet at HKD 1.605, the stock trades below both MA20 (HKD 1.754) and MA60 (HKD 1.812), with YTD decline of 44.66%, P/B of 0.75x, and P/E of 7.22x. Notably, the company has been actively repurchasing shares at HKD 1.85-1.92 for cancellation, signaling management‘s confidence in intrinsic value.

Edding Genor reversed sharply in the afternoon session, closing at HKD 1.70, down 5.03%, with an intraday range of 5.6% showing a spike-and-fall pattern. The stock briefly touched HKD 1.80 in the morning but weakened steadily after noon, hitting a new intraday low of HKD 1.70. A key sub-licensing deal collapsed after the upstream license was terminated, fueling concerns over pipeline execution. Despite strong Q4 2025 earnings—revenue up 20.5% YoY to HKD 751.7M, net profit surging 156.82% YoY to HKD 158.3M, and net margin at 21.06%—the stock remains 69.64% below its 52-week high of HKD 5.60 and trades below both its 20-day MA (HKD 1.783) and 60-day MA (HKD 1.836). However, recent share buybacks, including one at HKD 1.92, signal management's confidence.

Edding Genor Group rose 4.64% to HKD 1.805 in the morning session, recovering from an early low of 1.685 to hit an intraday high of 1.820 before easing. The company has executed nearly 10 share buybacks since June, signaling management confidence. This was further supported by NMPA approval for a Phase Ib/II trial of its trispecific breast cancer antibody GB268 and the realization of US$48.4 million from the sale of its Candid stake. Q4 revenue grew 20.5% YoY to HKD 751.7 million, with net profit surging 156.8% YoY to HKD 158.3 million, and EPS reaching HKD 0.0787. However, the stock is still down 37.76% YTD and 67.77% below its 52-week high of HKD 5.6, while trading near its 20-day MA (1.799) and below the 60-day MA (1.849), indicating a gradual recovery trajectory.